Share on LinkedInShare on LinkedIn

ARTICLE · 10 JUNE 2013

Supreme Court Amends Earlier Decision: Viagra Patent Not Void

In "Teva Canada Ltd v Pfizer Canada Inc.", the Supreme Court of Canada held Pfizer's Canadian Patent No. 2,163,446 to be "void".

CanadaIntellectual Property

In Teva Canada Ltd v Pfizer Canada Inc, the Supreme Court of Canada (the "SCC") held Pfizer's Canadian Patent No. 2,163,446 (the '446 Patent) to be "void" for not disclosing that sildenafil, the active ingredient in ViagraTM, was the compound that had been demonstrated to work in patients. (Please click here for further details.) The SCC has now revised and clarified the wording of its decision. However, the immediate effect of the revised decision on the marketplace has not changed because generic sildenafil still has marketing authorization and is available for sale in Canada.

The Background

The holding by the SCC that the '446 Patent was "void" was unusual in that the appeal had originated as an application brought by Pfizer under the Patented Medicines (Notice of Compliance) Regulations (the "PM(NOC) Regulations"). Teva (then Novopharm) had asserted to the regulator, Health Canada, that the '446 Patent was invalid and therefore should not prevent Teva

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from